Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;15(6):715-9.
doi: 10.1586/14737159.2015.1019476. Epub 2015 Mar 16.

Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq

Scott V Bratman  1 , Aaron M Newman, Ash A Alizadeh, Maximilian Diehn
Affiliations
Review

Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq

Scott V Bratman et al. Expert Rev Mol Diagn. 2015 Jun.

Abstract

Tumors continually shed DNA into the circulation, where it can be noninvasively accessed. The ability to accurately detect circulating tumor DNA (ctDNA) could significantly impact the management of patients with nearly every cancer type. Quantitation of ctDNA could allow objective response assessment, detection of minimal residual disease and noninvasive tumor genotyping. The latter application overcomes the barriers currently limiting repeated tumor tissue sampling during therapy. Recent technical advancements have improved upon the sensitivity, specificity and feasibility of ctDNA detection and promise to enable innovative clinical applications. Here, we focus on the potential clinical utility of ctDNA analysis using CAncer Personalized Profiling by deep Sequencing (CAPP-Seq), a novel next-generation sequencing-based approach for ultrasensitive ctDNA detection. Applications of CAPP-Seq for the personalization of cancer detection and therapy are discussed.

Keywords: biomarker; circulating tumor DNA; next-generation sequencing; noninvasive; ultrasensitive.

PubMed Disclaimer

References

    1. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science translational medicine. 2014 Feb 19;6(224):224ra224. - PMC - PubMed
    1. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. The New England journal of medicine. 2013 Mar 28;368(13):1199–1209. - PubMed
    1. Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. ASCO Meeting Abstracts. 2014 Jun 11;32(15_suppl):8504. 2014.
    1. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Apr 15;18(8):2391–2401. - PubMed
    1. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature medicine. 2014 May;20(5):548–554. - PMC - PubMed